Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Exchange Rate Effect (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Exchange Rate Effect for 9 consecutive years, with -$656000.0 as the latest value for Q4 2025.

  • Quarterly Exchange Rate Effect rose 66.32% to -$656000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 300.0% year-over-year, with the annual reading at $4.0 million for FY2025, 300.0% up from the prior year.
  • Exchange Rate Effect for Q4 2025 was -$656000.0 at Ultragenyx Pharmaceutical, down from $294000.0 in the prior quarter.
  • The five-year high for Exchange Rate Effect was $2.9 million in Q2 2025, with the low at -$1.9 million in Q4 2024.
  • Average Exchange Rate Effect over 5 years is -$13450.0, with a median of -$264000.0 recorded in 2021.
  • The sharpest move saw Exchange Rate Effect crashed 421.8% in 2024, then soared 549.69% in 2025.
  • Over 5 years, Exchange Rate Effect stood at -$392000.0 in 2021, then soared by 444.9% to $1.4 million in 2022, then tumbled by 52.59% to $641000.0 in 2023, then tumbled by 403.9% to -$1.9 million in 2024, then soared by 66.32% to -$656000.0 in 2025.
  • According to Business Quant data, Exchange Rate Effect over the past three periods came in at -$656000.0, $294000.0, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.